Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupEBOSY 85 EV-to-EBITDA is 10.09 as of Jul. 30, 2026, which is 25% below its 10-year median of 13.52. GuruFocus rates EBOSY with a GF Score™ of 85/100 and a GF Value™ of $47.52. The stock has 4 warning signs investors should review. Among 98 Medical Distribution companies, Ebos Group ranks worse than 61.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ebos Group's enterprise value is $3,699 Mil.
Ebos Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $367 Mil. Therefore, Ebos Group's EV-to-EBITDA for today is 10.09.
The historical rank and industry rank for Ebos Group's EV-to-EBITDA or its related term are showing as below:
EBOSY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.28 Med: 13.52 Max: 21.09
Current: 10.15
During the past 13 years, the highest EV-to-EBITDA of Ebos Group was 21.09. The lowest was 9.28. And the median was 13.52.
EBOSY's EV-to-EBITDA is ranked worse than 61.22% of 98
companies
in the Medical Distribution industry
Industry Median: 8.675
vs EBOSY: 10.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Ebos Group (OTCPK:EBOSY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ebos Group's share price for today is $26.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $1.472.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ebos Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ebos Group's EV-to-EBITDA falls into.
Ebos Group's current Enterprise Value is $3,699 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $367 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (EBOSY) has a EV-to-EBITDA of 10.09 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ebos Group. This is 25% below median its historical median of 13.52. Over the past decade, Ebos Group's EV-to-EBITDA has ranged from 9.28 to 21.09. According to the industry distribution chart, Ebos Group ranks #60 out of 98 companies in the Medical Distribution industry, placing it in the top 61.2%.
Is Ebos Group's EV-to-EBITDA too high?
Ebos Group's current EV-to-EBITDA of 10.09 is 25% below median its 10-year median of 13.52. Over the past 10 years, this metric has ranged from a low of 9.28 to a high of 21.09. The Medical Distribution industry median EV-to-EBITDA is 8.68. Ebos Group's value of 10.09 is 16.3% above this industry median. Based on the distribution chart, Ebos Group ranks #60 out of 98 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #60 out of 98 companies for EV-to-EBITDA. This places Ebos Group in the lower half of its industry. The industry median EV-to-EBITDA is 8.68. Ebos Group's value of 10.09 is 16.3% above this benchmark. Historically, Ebos Group's own EV-to-EBITDA has ranged from 9.28 to 21.09 over the past decade. While the company's 10-year median is 13.52 vs. the industry median of 8.68, Ebos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.68, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current EV-to-EBITDA of 10.09 is 16.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ebos Group. For the Medical Distribution industry, the median EV-to-EBITDA is 8.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current EV-to-EBITDA is 10.09, which is 25% below median its own 10-year median of 13.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSY) has a current EV-to-EBITDA of 10.09. The stock's GF Value™ is $47.52, compared to a current price of $26.00 — trading 45.3% below its estimated fair value. The current EV-to-EBITDA is 10.09, which is 25% below median its 10-year median of 13.52 and 16.3% above the Medical Distribution industry median of 8.68. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ebos Group (EBOSY), the current EV-to-EBITDA is 10.09 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSY) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $26.00 is trading 45.3% below its estimated GF Value™ of $47.52.
Key valuation signals for EBOSY:
EV-to-EBITDA: 10.09 (25% below median its 10-year median of 13.52)
GF Value™: $47.52 vs. price of $26.00 (45.3% below fair value)
Industry Position: 16.3% above the Medical Distribution median (#60 of 98)
No single metric tells the full story. See the EBOSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSY has been successfully added to your 
